Intra-Cellular Therapies Inc. (ITCI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Intra-Cellular Therapies Inc. (ITCI)
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Key Insights
Critical company metrics and information
Share Price
$83.72Market Cap
$8.88 BillionTotal Outstanding Shares
106.02 Million SharesTotal Employees
561Dividend
No dividendIPO Date
December 19, 2013SIC Description
Pharmaceutical PreparationsHomepage
https://www.intracellulartherapies.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities, Continuing | $-137.84 Million |
Net Cash Flow From Operating Activities | $-62.16 Million |
Net Cash Flow From Operating Activities, Continuing | $-62.16 Million |
Net Cash Flow From Financing Activities | $564.91 Million |
Net Cash Flow From Financing Activities, Continuing | $564.91 Million |
Net Cash Flow, Continuing | $364.91 Million |
Net Cash Flow | $364.91 Million |
Net Cash Flow From Investing Activities | $-137.84 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Income Tax Expense/Benefit | $1.24 Million |
Costs And Expenses | $704.83 Million |
Net Income/Loss Attributable To Parent | $-86.37 Million |
Net Income/Loss | $-86.37 Million |
Other Operating Expenses | $518.74 Million |
Income/Loss From Continuing Operations Before Tax | $75.10 Million |
Operating Income/Loss | $-121.62 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-86.37 Million |
Revenues | $613.73 Million |
Basic Average Shares | $206.20 Million |
Diluted Earnings Per Share | $-0.87 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Diluted Average Shares | $206.20 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Income/Loss From Continuing Operations After Tax | $-86.37 Million |
Operating Expenses | $735.35 Million |
Benefits Costs and Expenses | $538.63 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Basic Earnings Per Share | $-0.87 |
Research and Development | $216.61 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Other Non-current Assets | $50.71 Million |
Fixed Assets | $2.00 Million |
Liabilities And Equity | $1.32 Billion |
Equity | $1.14 Billion |
Assets | $1.32 Billion |
Equity Attributable To Parent | $1.14 Billion |
Other Current Assets | $1.25 Billion |
Current Liabilities | $166.11 Million |
Accounts Payable | $10.34 Million |
Noncurrent Assets | $52.71 Million |
Inventory | $23.54 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $179.62 Million |
Noncurrent Liabilities | $13.51 Million |
Other Current Liabilities | $155.78 Million |
Current Assets | $1.27 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.